ETHZilla Corp — Director's Dealing 2025

Feb 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 180 Life Sciences Corp. (ATNF)
CIK: 0001690080
Period of Report: 2025-02-20

Reporting Person: Jordan Blair (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-20	Common Stock	A	160000	$0.0	Acquired	160000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	43166	Indirect

Footnotes

F1: On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

F2: As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.

F3: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of January 1, 2026 and December 31, 2026, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3.

F4: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan.